Status:
RECRUITING
Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia
Lead Sponsor:
University of Pittsburgh
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of th...
Detailed Description
Antioxidant therapies targeted to specific enzymes or compartments may be beneficial in sickle cell anemia (SCA). MitoQ, the most extensively studied mitochondrial-targeted antioxidant, has been shown...
Eligibility Criteria
Inclusion
- Subjects
- African American
- Patients with sickle cell anemia
- 18 years old or older
- Control
- African American healthy controls
- 18 years of age or older
Exclusion
- Pregnancy,
- Known hypertension,
- Hemodialysis and active obstructive sleep apnea requiring treatment.
- Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04109820
Start Date
March 1 2020
End Date
June 30 2027
Last Update
June 19 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Magee Women's Hospital
Pittsburgh, Pennsylvania, United States, 15213
2
UPMC Montefiore
Pittsburgh, Pennsylvania, United States, 15213
3
UPMC Presbyterian
Pittsburgh, Pennsylvania, United States, 15213
4
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15224